Global Markets for Diabetes Therapeutics and Diagnostics
The global diabetes market should reach $155 billion by 2021 from $125 billion in 2016 at a compound annual growth rate (CAGR) of 4.4%, from 2016 to 2021.
- An overview of the global market for diabetes
- Analyses of global market trends, with data from 2015, estimates for 2016, and projections of CAGRs through 2021.
- Analysis of the devices and instruments used in the diagnosis and monitoring of diabetes
- A close look at major forces contributing to the vigorous growth of the diabetes market
- Evaluation of other factors influencing the market such as health care policies, demographics, and the wider economic environment
- Discussion covering companies in the relevant pharmaceutical and medical industries through company profiles of many leading players in the field
This report discusses the implications of the above-mentioned trends, in the context of the current size and growth of the diabetes market, in global terms as well as by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the main drug and device categories, and breakdowns of the diabetes market are provided by country.
A comprehensive refresher section on diabetes is provided as an appendix.
Paul Evers has been involved in analyzing pharmaceutical and medical markets for 20 years. He is the author of previous BCC Research reports on the diabetes marketplace covering both therapeutic and monitoring aspects.
The global market for diabetes therapeutics and diagnostics was valued at $110 billion in 2011 and should reach nearly $118.7 billion in 2012. Total market value is expected to reach nearly $157 billion in 2017 after increasing at a five-year compound annual growth rate (CAGR) of 5.7%.
The global market for therapeutic and diagnostic products for diabetes is valued at $38 billion in 2010. This market is expected to grow at a compound annual growth rate (CAGR) of 6.1% to reach $51.2 billion in 2015.
Insulin products, including administration devices, are worth an estimated $16.4 billion in 2010. This sector is expected to reach $22 billion in 2015, a 6.1% compound annual growth rate (CAGR).
Oral hypoglycemic drugs are expected to achieve the highestcompound annual growth rate (CAGR) of 8%, increasing from $10.3 billion in 2010 to $15.1 billion in 2015.
- The global market for diabetes therapeutics and diagnostics increased from $208.5 billion in 2007 to an estimated $213.8 billion by the end of 2008. It should reach $241.9 billion by 2013, a compound annual growth rate (CAGR) of 2.5%.
- The global diabetes market will become one of the largest healthcare markets over the next five years, due in large part to the epidemic explosion of the type II diabetes population.
- Over the next five years, market leaders will overcome technology barriers to bring non-invasive, insulin-dependent products to the market.
The total market for diabetes drugs and devices is estimated at $18 billion in 2002. Growing at an average annual rate (AAGR) of 11.5%, the market is expected to exceed $30.7 billion in 2007.
Drug sales in 2002 are expected to be $12.5 billion, increasing to almost $21 billion by 2007 at an AAGR of 10.3%.
Insulin was 33% of the market in 2000 and is expected to hold on to that share.
Sulfanylureas and biguanides are expected to lose considerable market share to generics, newer classes of drugs, and to the extremely popular thiazolidinediones.
The two major diabetes medical devices are glucose monitors and insulin pumps. Glucose monitors are expected to rise at an AAGR of 13.7% to $8 billion by 2007. Insulin pumps are expected to grow to $1.8 billion by 2007 at an AAGR of 18.7%.